Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript
Anika Therapeutics, Inc. ( ANIK ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Matt Hall Cheryl Blanchard - President, CEO & Director Stephen Griffin - Executive VP, CFO & COO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Anika's third quarter earnings conference call. [Operator Instructions] I will now turn the call over to Matt Hall, Director, Corporate Development and Investor Relations.
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.25 per share a year ago.
Anika (ANIK) Upgraded to Buy: Here's What You Should Know
Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts
Anika Therapeutics is an HA-platform company with regenerative, OA pain, and non-orthopedic products. Their main line is called Integrity. But Hyalofast and Cingal can also eventually target the sizeable cartilage and OA markets. ANIK's Integrity outperformed since launch, and their regenerative solutions have grown YoY. That's why the company believes it can also tap into the tendon-augmentation TAM.
Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Cheryl Renee Blanchard - President, CEO & Director Matt Hall - Corporate Participant Stephen D. Griffin - Executive VP, CFO & COO Conference Call Participants Anderson Schock - B.
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago.
Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Anderson Schock - B. Riley Securities Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company.
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.31 per share a year ago.
Is the Options Market Predicting a Spike in Anika Therapeutics Stock?
Investors need to pay close attention to ANIK stock based on the movements in the options market lately.
Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Year End Earnings Conference Call. At this time, all lines are in listen-only mode.
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - President and CEO Steve Griffin - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. [Operator Instructions].
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.30. This compares to loss of $0.45 per share a year ago.
